Kornimate/medical-research-clean huggingface dataset:
efficacy and safety study of combination of ginkgo extract and ginseng extract in children with adhd(attention deficit hyperactivity disorder)

Conditions: Mental Disorders

Summary: this study will evaluate clinical efficacy and safety of treatment with yy-162 in children with adhd.

this is double-blind, two arms, multi-center, interventional, 8 weeks study starting with yy-162(combination of ginkgo extract and ginseng extract)in children with adhd. assessment of efficacy and safety will be performed at the baseline, weeks 2, 4 and 8. at the first visit, a full psychiatric history, demographic date and physical examination will be undertaken. throughout the study, the following procedures, documentations and evaluations will performed; k-ars, iowa conner's rating scale, cgi-s/i, ata, children's color trails test and stroop test, intelligence test(from kedi-wisc)and adverse event reporting.

Eligibility criteria:
inclusion criteria: * mele and female subjects aged from 6 to 15 * subjects must meet dsm-iv criteria for adhd based-on the k-schedule for affective disorder and schizophrenia(k-sads-pl-k)interview * subjects signed a written consent form voluntarily * patient's assent to participate in the study and written informed consent form signed by one of the parents, parent surrogates or legal guardian. * subjects who can keep visit schedule and whose parent/parent surrogates or legal guardian can willingly complete assessments defined in the study protocol. * subjects/parents, parent surrogates or legal guardian who can understand the participation of the study and voluntarily withdraw from the study at any time. exclusion criteria: * subjects who have difficulty swallowing tablet. * subjects who have known allergy to plant extracts. * subjects who meet dsm-iv diagnostic criteria for current major depressive disorder or anxiety disorder requiring drug therapy. * subjects who have any history of bipolar disorder, psychotic disorder, and substance use disorder, have been diagnosed with a pervasive developmental disorder, organic brain disease and seizure disorder. * subjects who have significant suicidal ideation. * subjects with mental retardation. * subjects with tourette's syndrome requiring drug therapy. * subjects who have been administrated methylphenidate or atomoxetine within recent 3 months and ginkgo extract or ginseng extract within recent 1 month. * subjects who currently have a significant medical conditions(e.g. diseases of cardiovascular, hepatic, renal, respiratory, glaucoma) * subjects who have abnormalities in the ecg or show clinically significant abnormalities of laboratory results including serum chemistries and hematology. * subjects who are currently taking alpha-2 adrenergic receptor agonist, antidepressant, antipsychotic, benzodiazepines, modafinil, anticonvulsant. * subjects who receive psychosocial treatment during the drug trial. * subjects who are not able to swallow the study drug.

Keywords: adhd(attention deficit hyperactivity disorder)
cfdna in diagnosis and differential diagnosis of ovarian endometriosis

Conditions: Circulating Free DNA

Summary: methylation detection of circulating free dna to identify markers for diagnosis and differential diagnosis of ovarian endometriosis.

methylation detection of circulating free dna and ffpf samples from patients with ovarian endometriosis, ovarian cancer and other benign ovarian cysts will be performed to select markers for ovarian endometriosis diagnosis. the markers will be validated in patients with ovarian cysts found by ultrasound. the diagnosis accuracy of the markers will be evaluated by comparing with the pathological diagnosis.

Eligibility criteria:
1. marker selection group: 1. patients with ovarian endometriosis: inclusion criteria: 1. pathologically diagnosed as ovarian endometriosis; 2. surgery was performed in pumch exclusion criteria: a. combined with other gynecological benign and malignant tumors; b. clinically suspected malignant tumors; c. combined with other systemic malignancies or malignancies history; d. pregnant patients 2. patients with ovarian cancer: inclusion criteria: 1. pathologically diagnosed as epithelial ovarian cancer; 2. surgery was performed in pumch exclusion criteria: 1. combined with gynecological benign tumors and other malignant tumors; 2. combined with other systemic malignancies or malignancies history; 3. pregnant patients (3) patients with other benign ovarian tumors: inclusion criteria: 1. pathologically diagnosed as benign ovarian tumors but not ovarian endometriosis; 2. surgery was performed in pumch exclusion criteria: a. combined with other gynecological benign and malignant tumors; b. clinically suspected malignant tumors; c. combined with other systemic malignancies or malignancies history; d. pregnant patients 2. marker validation group: inclusion criteria: 1. ovarian cysts found through ultrasound ; 2. surgery will be performed in pumch exclusion criteria: 1. combined with other gynecological benign and malignant tumors; 2. clinically suspected malignant tumors; 3. combined with other systemic malignancies or malignancies history; 4. pregnant patients
the effect of moxonidine on blood pressure and regression of early target organ damage in young subjects with abdominal obesity and hypertension

Conditions: Abdominal Obesity; Hypertension

Summary: obesity is a major risk factor for the development of hypertension. based on population studies, risk estimates indicate that at least two-thirds of the prevalence of hypertension can be directly attributed to obesity. obesity per se is commonly associated with activation of the sympathetic nervous system with a predominant increase in sympathetic outflow to the kidneys and the peripheral vasculature and there is now conclusive evidence that heightened sympathetic nerve activity is a major contributor to the elevation in blood pressure associated with obesity, particularly in young subjects. in line with these findings, dietary weight loss has repeatedly been demonstrated to result in reduced sympathetic nerve activity and lower blood pressure levels. several lines of evidence have well documented the significant role of sns activation in obesity associated hypertension and target organ damage. weight loss is the preferred treatment option for obesity and its consequences and reduces both sns activation and blood pressure. in the real world however, weight loss maintenance is rarely achieved in obese patients highlighting the urgent need for alternative treatment strategies. given the crucial involvement of sns activation in various aspects of the obesity related increase in blood pressure, target organ damage and cardiovascular risk, the use of sympatho-inhibitory agents at an early stage is an obvious choice. the investigators therefore plan to examine the effects of the centrally sympatholytic agent moxonidine on blood pressure and the morning surge in blood pressure, sympathetic activity, regression of early target organ damage (heart, kidney and endothelium), metabolic and inflammatory markers in young obese subjects with hypertension in a randomized, double-blind clinical trial with the angiotensin receptor blocker irbesartan as an active comparator to achieve similar blood pressure reductions in both groups. the investigators hypothesize that moxonidine treatment will result in significant improvements in these outcome parameters and beneficial effects beyond simple blood pressure reduction. findings from this study could pave the way for an early and pathophysiology- tailored treatment strategy of obesity related hypertension and its detrimental consequences.


Eligibility criteria:
inclusion criteria: * male age 18-30 years old * presence of central obesity and hypertension * no history of cardiovascular disease or depression * not on any medication exclusion criteria: * history of cardiovascular disease, depression or anxiety disorder

Keywords: male age 18-30 years old presence of central obesity no history of cardiovascular disease, depression not on any medication
a study to evaluate ocrelizumab in combination with methotrexate compared with infliximab plus methotrexate in patients with active rheumatoid arthritis currently responding inadequately to etanercept or adalimumab

Conditions: Rheumatoid Arthritis

Summary: this is a phase ii, randomized, active-controlled, double-blind, double-dummy, parallel-group, multicenter study in the united states enrolling patients with active ra. the study will enroll approximately 290 patients at approximately 130 sites.


Eligibility criteria:
inclusion criteria: * age \>= 18 years * current treatment for ra on an outpatient basis * active disease * currently receiving 50 mg etanercept subcutaneously (sc) every week or 40 mg adalimumab sc every other week. * considered by investigator to be a primary non-responder to their first anti-tnfî± treatment for efficacy reasons exclusion criteria: * rheumatic autoimmune disease other than ra, or significant systemic involvement secondary to ra * history of, or current, inflammatory joint disease other than ra (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, lyme disease) or other systemic autoimmune disorder (e.g., systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease or other overlap syndrome) * previous treatment with a any biologic therapy for ra (including investigational products with the exception of etanercept or adalimumab * treatment with more than one prior anti-tnfî± therapy

Keywords: ra arthritis
maximum targeted ablation of atrial flutter

Conditions: Atrial Flutter

Summary: patients undergoing atrial flutter ablation will be randomized to either the standard ablation approach or voltage targeted approach. patients will be followed for one year to assess outcome of the ablation technique


Eligibility criteria:
inclusion criteria: * patients undergoing tv-ivc isthmus ablatin for atrial flutter exclusion criteria: * atypical atrial flutter * \<18 years old any atrial surgery or pacemaker refusal to participate

Keywords: atrial flutter ablation voltage targeted
micro assays for hematology malignancies antibody treatment

Conditions: Hematological Malignancy

Summary: hematological malignancy is a disease of the blood. in some cases, this pathology requires therapeutic management, which is not necessarily the case for you. nevertheless, to improve the management of patients who need it, we are conducting research to assess the state of your immune system. indeed, the role of the immune system is not limited to controlling infections, but is also important in controlling the proliferation of cancer cells, in hematology as in other types of cancer. your immune system can play a spontaneous anti-tumor control role, but some so-called "immunotherapy" treatments aim to destroy cancer cells by stimulating the immune system, restoring its capabilities, and directing the immune response against tumor cells. for this immunotherapy treatment to be effective, since it uses your own immune cells (in most cases), these cells must be in a state to respond and be able to destroy the tumor. it is this ability to activate immune cells that is tested in this research protocol, using a simple test that could in future be used in routine clinical practice. but to understand why these immune cells don't work, we will also have to carry out genetic tests to analyze the various molecules that could interfere with the immune response, and try to inhibit the molecules that prevent the immune response.


Eligibility criteria:
inclusion criteria: * male or female over 18 years of age * patient with a hematological malignancy likely to benefit from immunotherapy (in any form; at the discretion of the referring physician) * before the start of 1st-line treatment, successive lines or before autograft (chemotherapy-free for at least 4 weeks in these cases). * patient has received information about the study and has not expressed opposition. * patient who is a beneficiary or entitled beneficiary of a social security scheme exclusion criteria: * person in a period of exclusion from another research protocol at the time the non-opposition is signed. * subjects covered by articles l1121-5 to 1121-8 of the french public health code, i.e. : * persons deprived of their liberty by judicial or administrative decision * persons subject to psychiatric monitoring under articles l3112-1 and l3113-1 who are not covered by the provisions of article l1121-8 * minors * adults under legal protection or unable to express their consent. * a person who cannot read and understand the french language well enough to be able to consent to take part in research.
on-eye evaluation of contact lens axis location

Conditions: Myopia; Astigmatism; Refractive Error

Summary: the purpose of this study was to evaluate the axis location of toric contact lenses after 3 minutes of wear. during this 1-visit study, each participant wore 3 pairs of study lenses of various design iterations (2-87-1, 2-87-2, 2-87-3) for an exposure time of approximately 30 minutes each. each pair consisted of lenses of the same design iteration, 1 lens with embossed mark \[test1 (t1), test3 (t3), test5 (t5)\], worn on the right eye, and 1 lens without embossed mark \[test2 (t2), test4 (t4), and test6 (t6)\] worn on the left eye.


Eligibility criteria:
inclusion criteria: * sign written informed consent. * best corrected distance visual acuity greater than or equal to 20/25 in each eye. * other protocol-defined inclusion criteria may apply. exclusion criteria: * history of any ocular surgery or ocular injury within 12 weeks of enrollment for this study. * anterior segment disease, infection, inflammation, or abnormality that contraindicates contact lens wear. * history of herpetic keratitis. * slit-lamp findings at baseline as specified in the protocol. * any use of systemic or ocular medications for which contact lens wear could be contraindicated, including ocular medications that require instillation during contact lens wear. * clinically significant dry eye not responding to treatment. * history of refractive surgery. * other protocol-defined exclusion criteria may apply.

Keywords: contact lens toric
optimizing the approach of mobile application use to improve medication adherence in patients with hypertension

Conditions: Medication Adherence; Hypertension

Summary: the purpose of this study was to determine the effectiveness of using a custom-designed mobile application to improve blood pressure (bp) and promote adherence to antihypertensive medication regimens. this was a prospective, multicenter, randomized controlled trial. patients were randomized to an intervention or control group for three months. antihypertensive medication refill history was assessed three months before, during and three months after the study period. continuous outcome measures investigated were systolic/diastolic bp and medication refill history, using the cumulative medication gap (cmg) score.


Eligibility criteria:
inclusion criteria: * 18 years of age * diagnosed with hypertension as evidenced by diagnosis codes or chart documentation * prescribed at least one antihypertensive for a minimum of three months prior to enrollment * have access to an android mobile device with data capabilities * consent to using the application on their device exclusion criteria: * do not read or speak english * unable to read and sign the informed consent or health insurance privacy and accountability act (hipaa) waiver * too ill or cognitively impaired to participate
safety/efficacy of intravenous zoledronic acid when added to standard therapies in patients with breast cancer and metastatic bone lesions

Conditions: Breast Cancer With Bone Metastasis

Summary: zoledronic acid selectively binds to bone and protects it from being metastasized by tumor cells. this study evaluates the safety and efficacy of zoledronic acid when added to standard therapies in breast cancer patients with metastatic bone lesions.


Eligibility criteria:
inclusion criteria * confirmed diagnosis of breast cancer with at least one breast cancer-related bone lesion * no treatment with bisphosphonates within 6 months prior to inclusion into the study * good health status (ecog performance status 0-2) exclusion criteria * patients who do not have at least one breast cancer-related bone lesion that is detectable on conventional radiographs of bone (plain film) at screening * abnormal renal function * history of diseases with influence on bone metabolism such as paget's disease and primary hyperparathyroidism * pregnancy and lactation * current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (onj), of exposed bone in the mouth, or of slow healing after dental procedures, recent (within 6 weeks) or planned dental or jaw surgery (e.g..extraction, implants)

Keywords: breast cancer palliation bone metastasis zoledronic acid
tbe-vaccine to patients with rheumatoid arthritis who are using immunosuppressive drugs

Conditions: Rheumatoid Arthritis; Exposed to TBE-virus; Immunosuppression

Summary: the investigators intend to check whether the efficacy of a tbe-vaccine is substantially deteriorated in patients with rheumatoid arthritis who are treated with drugs which suppress the immune system. the investigators aim to detect a difference of at least 10 % compared to healthy individuals (historical controls) in protection when analysed with serology. if the investigators detect a difference, the investigators will continue to explore whether protection can be achieved by additional doses


Eligibility criteria:
inclusion criteria: * rheumatoid arthritis treated with methotrexate and/or tnf-alfa blocking drugs * interest to be vaccinated * written consent * age 18 years or more exclusion criteria: * previous tbe-infection * previous vaccination with tbe * pregnancy * breast feeding * treatment with rituximab the last 9 months * inability to follow study protocol

Keywords: rheumatoid arthritis tbe-vaccine immunosuppression
the relationship between voiding dysfunction and intravesical sensory threshold in diabetes women

Conditions: Diabetes Mellitus

Summary: the investigators will recruit a cross-sectional group of diabetic women in internist clinics. uds will be applied for voiding function in each case. intravesical electrical stimulation will be used to test cpt per 5 hz, 250 hz, 2000 hz for the patients. the differences of intravesical cpt between diabetic women with and without voiding dysfunction will be determined.

diabetes is a common metabolic disease of multiorgan involvement. the american diabetes association reported that the prevalence of diagnosed and undiagnosed diabetes mellitus (dm) in the united states is currently 6% and rising. the increase is secondary to a rising incident in obesity, as well as a change in the criteria for the diagnosis of dm from a fasting blood glucose 140 mg/dl to 126 mg/dl. besides impaired blood glucose regulation, many direct and indirect sequelae of dm can occur. triopathy of diabetes including retinopathy, neuropathy, and nephropathy are familiar to every internist. lower urinary tract dysfunction is one of the most common complications in this group of patients. we look at the difference of intravesical sensation in diabetic women by current perception test; then, we can find the patient with diabetic cystopathy in early stage. we compare the groups of diabetic women with or without voiding dysfunction by urodynamic study. cpt test for intravesical sensation will be applied.

Eligibility criteria:
inclusion criteria: * the diabetic women followed up in specialist clinics over one year at national taiwan university hospital (ntuh) exclusion criteria: * concurrent neurological problems or other medical conditions that might interfere with voiding function * acute urinary tract infection (uti) * previous pelvic surgery * vaginal prolapse

Keywords: diabetic cystopathy bladder voiding dysfunction current perception test
mk0767 glipizide comparator cardiac safety study (0767-018)

Conditions: Diabetes Mellitus, Type 2

Summary: a study to evaluate the cardiac and metabolic effects of mk0767 in patients with type 2 diabetes. this is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (full information is available to trial participants).


Eligibility criteria:
inclusion criteria: * you are taking at least one medication for high blood sugar * age 21 to 80 exclusion criteria: * history of type 1 diabetes mellitus * currently on estrogen replacement therapy regimen * currently on a weight loss program with ongoing weight loss or taking medications for weight loss * having surgery 30 days before starting the study * have taken any other investigational drug in the past 90 days * have hepatitis b or c * active liver or gallbladder disease
phase 1/2 study exploring the safety, tolerability, and efficacy of incagn01876 combined with immune therapies in advanced or metastatic malignancies

Conditions: Advanced Malignancies; Metastatic Cancer

Summary: the purpose of this study is to determine the safety, tolerability, and efficacy of incagn01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.


Eligibility criteria:
inclusion criteria: * locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent. * phase 1: subjects with advanced or metastatic solid tumors. * phase 1: subjects who have disease progression after treatment with available therapies. * phase 2: subjects with advanced or metastatic cervical cancer, gastric cancer (including stomach, esophageal, and gej), scchn, pd-1 refractory scchn and pd-1/pd-l1 relapsed melanoma. * presence of measurable disease based on recist v1.1. * eastern cooperative oncology group (ecog) performance status 0 to 1. exclusion criteria: * laboratory and medical history parameters not within the protocol-defined range * prior treatment with any tumor necrosis factor super family agonist. * receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug. * has not recovered to ≤ grade 1 from toxic effects of prior therapy. * active autoimmune disease. * known active central nervous system metastases and/or carcinomatous meningitis. * evidence of active, noninfectious pneumonitis or history of interstitial lung disease. * evidence of hepatitis b virus or hepatitis c virus infection or risk of reactivation. * known history of human immunodeficiency virus (hiv; hiv 1/2 antibodies).

Keywords: cervical cancer endometrial cancer gastric cancer (stomach, esophageal, and gastroesophageal junction [gej]) hepatocellular carcinoma (hcc) melanoma merkel cell carcinoma mesothelioma microsatellite instability-high (msi-h) colorectal cancer (crc) non-small cell lung cancer (nsclc) ovarian cancer squamous cell carcinoma of the head and neck (scchn) small cell lung cancer (sclc) renal cell carcinoma (rcc) triple-negative breast cancer (tnbc) urothelial carcinoma glucocorticoid-induced tumor necrosis factor receptor (gitr)